San Francisco, California – September 3, 2026
The U.S. Food and Drug Administration has approved Zanvastro (zilganersen) injection for the treatment of Alexander disease in pediatric and adult patients, marking the first FDA-approved therapy to directly target the underlying cause of this rare and devastating neurological disorder.
For the estimated 300 people living with Alexander disease in the United States, the approval ends decades of therapeutic hopelessness. Until now, treatment has been limited to managing symptoms while the disease progresses.
A Decade in the Making
The approval represents the culmination of roughly 15 years of research into Alexander disease biology and clinical development. The condition, first described in 1949 by British neurologist W. Stewart Alexander, affects approximately 1 in 1 million to 3 million people worldwide.
Alexander disease is caused by mutations in the GFAP gene, which produces glial fibrillary acidic protein. When this protein becomes abnormal, it accumulates in astrocytes—the brain's supportive cells—causing progressive damage to the nervous system. Symptoms range from seizures and developmental delays in infants to difficulty walking, muscle weakness, and increased brain pressure in older patients.
RNA-Targeted Precision Medicine
Zanvastro is an antisense oligonucleotide designed by Ionis Pharmaceuticals to reduce production of the abnormal GFAP protein before it accumulates and causes further damage. The drug is administered as a 50mg intrathecal injection into the spinal canal every three months by trained healthcare professionals.
The mechanism targets the disease at its source: instead of managing symptoms, Zanvastro reduces the buildup of the toxic protein that drives neurological deterioration. This represents a fundamental shift from palliative care to disease modification.
"For patients with Alexander disease and their families, there have been no approved treatment options — only supportive care while the disease progresses. Today's approval is a landmark moment for this community, offering the first therapy that addresses the underlying cause of this rare and serious disease." — Dr. Emily Freilich, Director of the Division of Neurology I, FDA Center for Drug Evaluation and Research
Trial Evidence and Age Range
The FDA evaluated evidence from a multicenter, randomized, controlled clinical study (NCT04849741) that enrolled 49 pediatric and adult patients aged 2 years and older, plus an open-label substudy of 4 children under 2 years.
For patients aged 5 and older with baseline walking difficulties, Zanvastro-treated patients showed significantly better walking speed at 61 weeks compared to controls. In children aged 2 to 4, where walking speed is less reliable, broader motor skill assessments showed improvement in treated patients while controls declined.
For children under 2 years, direct trial data were limited by the disease's rarity. The FDA accepted pharmacokinetic modeling showing drug levels would be similar to older children at the same dose, supported by safety data from four treated infants.
Safety Profile
The most common side effects include vomiting, back pain, cough, headache, and post-lumbar puncture syndrome. Patients should notify their healthcare provider if meningitis-like symptoms develop, as aseptic meningitis has been reported.
Zanvastro received Orphan Drug, Fast Track, Breakthrough Therapy, and Rare Pediatric Disease Priority Review Voucher designations from the FDA—reflecting both the serious nature of Alexander disease and the agency's commitment to rare disease drug development.
Price and Access
Ionis Pharmaceuticals will launch Zanvastro at $285,000 per dose, or approximately $1.14 million annually with quarterly dosing. The company has established financial assistance and reimbursement support programs to help patients access treatment.
The drug will be available through 12 leukodystrophy centers of excellence in the United States, ensuring patients have access to specialized care.
Implications for Neurodegenerative Research
The approval demonstrates the growing viability of antisense oligonucleotide therapy for neurological conditions. Similar RNA-targeted approaches are now in development for Huntington disease, spinal muscular atrophy, and other rare neurodegenerative disorders.
"This transformative approval also marks our first independent launch from our industry-leading neurology pipeline and underscores the power of our RNA-targeted technology to address serious neurological diseases without adequate treatment options." — Brett P. Monia, Chief Executive Officer, Ionis Pharmaceuticals
What Comes Next
With Zanvastro's approval, researchers can now focus on optimizing dosing schedules, expanding access, and studying long-term outcomes. The FDA may require post-marketing studies to confirm sustained clinical benefit.
For families living with Alexander disease, the approval offers the first realistic hope that disease progression can be slowed or potentially halted.
Source: U.S. Food and Drug Administration News Release, September 3, 2026. Ionis Pharmaceuticals Press Release, September 3, 2026.
FIRAT Editorial Board
Institutional Research Desk · Foresight Institute of Research and Translation
The collective editorial and research translation board of FIRAT, synthesising peer-reviewed evidence, policy briefs, and division milestones across our seven foundational research pillars.
